57469-77-9
57469-77-9 structure
- Name: Ibuprofen Lysine
- Chemical Name: (2S)-2,6-diaminohexanoic acid,2-[4-(2-methylpropyl)phenyl]propanoic acid
- CAS Number: 57469-77-9
- Molecular Formula: C19H30N2O3
- Molecular Weight: 352.468
- Catalog: Biochemical Amino acids and their derivatives Lysine derivative
- Create Date: 2018-06-12 16:40:15
- Modify Date: 2024-01-11 12:39:01
-
Ibuprofen ((±)-Ibuprofen) L-lysine is a potent orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen L-lysine inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen L-lysine is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen L-lysine can be used in the research of pain, swelling, inflammation, infection, immunology, cancers[1][2][3][4][5][6][7][8].
| Name | (2S)-2,6-diaminohexanoic acid,2-[4-(2-methylpropyl)phenyl]propanoic acid |
|---|---|
| Synonyms |
L-Lysine, compd. with α-methyl-4-(2-methylpropyl)benzeneacetic acid (1:1)
S1518_Selleck Ibuprofen lysine (USAN) Ibuprofen Lysinate 2-(4-Isobutylphenyl)propanoic acid - L-lysine (1:1) NeoProfen Ibuprofen Lysine EINECS 260-751-7 MFCD01716155 Neoprofen (TN) |
| Description | Ibuprofen ((±)-Ibuprofen) L-lysine is a potent orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen L-lysine inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen L-lysine is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen L-lysine can be used in the research of pain, swelling, inflammation, infection, immunology, cancers[1][2][3][4][5][6][7][8]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 13 μM (COX-1), 370 μM (COX-2) |
| In Vitro | Ibuprofen (24 h) L-lysine inhibits COX-1 and COX-2 activity with IC50 values of 13 μM and 370 μM[1]. Ibuprofen (500 μM, 48 h) L-lysine inhibits cell proliferation and angiogenesis, and induces apoptosis in AGS cells (Adenocarcinoma gastric cell line)[2]. Ibuprofen (500 μM, 48 h) L-lysine downregulates transcription of Akt, VEGF-A, PCNA, Bcl2, OCT3/4 and CD44 genes, but upregulates RNA levels of wild type P53 and Bax genes in AGS cell[2]. Ibuprofen (500 μM, 24 h) L-lysine restores microtubule reformation, microtubule-dependent intracellular cholesterol transport, and induces extension of microtubules to the cell periphery in both cystic fibrosis (CF) cell models and primary CF nasal epithelial cells[3]. Ibuprofen (500 μM, 24 h) L-lysine enhances UV-induced cell death in MCF-7 cells and MDA-MB-231 cells by a photosensitization process[4]. Cell Viability Assay[2] Cell Line: AGS cells Concentration: 100-1000 μM Incubation Time: 24 h, 48 h Result: Inhibited AGS cell viability with IC50 values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining, 48 h) and 408 μM (neutral red assay, 48 h). |
| In Vivo | Ibuprofen (300 mg/kg; p.o.; daily, for 14 days) L-lysine reduces overall tumor growth and enhances anti-tumor immune characteristics without adverse autoimmune reactions in a model of postpartum breast cancer[5]. Ibuprofen (60 mg/kg; i.h.; every second day for 15 days) L-lysine reduces the risk of neuropathy in a rat model of chronic Oxaliplatin‑induced peripheral neuropathy[6]. Ibuprofen (20 mg/kg; p.o.; every 12 hours, 5 doses total) L-lysine decreases muscle growth (average muscle fiber cross-sectional area) without affecting regulation of supraspinatus tendon adaptions to exercise[7]. Ibuprofen (35 mg/kg; p.o.; twice daily) L-lysine attenuates the Inflammatory response to pseudomonas aeruginosa in a rat model of chronic pulmonary infection[8]. Animal Model: Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum)[5] Dosage: 300 mg/kg, daily for 14 days Administration: Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly) Result: Suppresed tumor growth, reduced presence of immature monocytes and increased numbers of T cells. Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells. Animal Model: Oxaliplatin‑induced peripheral neuropathy[6] Dosage: 60 mg/kg, every second day for 15 days Administration: Subcutaneous injection Result: Lowered sensory nerve conduction velocity (SNCV). |
| References |
| Boiling Point | 319.6ºC at 760 mmHg |
|---|---|
| Molecular Formula | C19H30N2O3 |
| Molecular Weight | 352.468 |
| Exact Mass | 352.236206 |
| PSA | 95.41000 |
| LogP | 3.91530 |
| Storage condition | -20℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|